About
Originally founded in 2013 with technology spun out of the Weizmann Institute of Science, miCure leverages its deep understanding of the role of microRNAs in the biology of psychiatric diseases. More recently, the company has expanded its scientific and technological scope to include neurodegenerative and neurologic diseases, as well as other classes of RNAi therapeutics and novel methods to deliver oligonucleotides to the CNS.
Based on miR-135
mir-135 is a key modulator of depression and anxiety in numerous animal models
Selective
No reduction of post-synaptic HTR1A
Biologic effect
Serotonin brain levels increase
Technology
Non-invasive brain delivery
Dual activity
Modulates both Serotonin transporter and HTR1a auto receptor
Precision medicine
Ability to target specific neurons in the dorsal raphe nucleus
High profile
Immunologically safe
Technology
Proprietary non-invasive oligonucleotide brain delivery technology. It allows precise delivery of siRNA, miRNA and ASOs to modulate gene expression in specific cells.
The technology consists of linking the oligonucleotide of interest to a small molecule ligand that binds to neurotransmitter transporters or GPCR receptors.
Pre-clinical data in rodent and non-human primate models, including proof-of-concept studies showing viability of intranasal (“nose-to-brain”) administration of oligonucleotide conjugates
Literature
News
Phone
+34663885719
Email Address
info@micurerx.com
Address
Amot Investment Tower, 2 Weizmann St., 24th Floor Tel-Aviv 6423902 , Israel